Drug intelligence / Profile preview

ENB109

Development stage: Preclinical
Lead developer: EnnovaBio
Modality: Small Molecules

Overview

ENB109 is a small molecule drug under development by EnnovBio (Shanghai Ennovabio Pharmaceuticals) for the treatment of Alzheimer's disease and psoriasis. It is classified as both an antidementia and antipsoriatic agent. As of August 2024, its mechanism of action has not been defined or disclosed publicly. The drug is considered a new molecular entity and has reached preclinical development stages in China for both Alzheimer's disease and psoriasis[1][3].

Other names: ENB 109ENB109ENB-109

Beyond the preview

Go deeper on ENB109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENB109.

Explore the full profile